Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

This study is testing whether a drug called nanocrystalline megestrol acetate can help prevent weight loss in patients with locally advanced non-small cell lung cancer (NSCLC) who are undergoing concurrent chemotherapy and radiation. Weight loss during cancer treatment is common and worsens outcomes. **You may be eligible if...** - You are 18 years old or older - You have confirmed stage III (locally advanced) non-small cell lung cancer that cannot be surgically removed - You are planned to receive chemotherapy and radiation at the same time (concurrent chemoradiotherapy) - Your BMI is 25 or below - You have at least one measurable tumor and your expected survival is at least 6 months - Your overall health status is reasonable (ECOG 0–2) **You may NOT be eligible if...** - You have significant digestive or absorption problems - You have had prior treatment for this lung cancer - You have other serious health conditions making this treatment unsafe Talk to your doctor to see if this trial is right for you.